Replimune Group (NASDAQ:REPL) Releases Earnings Results, Beats Expectations By $0.02 EPS
Replimune Group (NASDAQ:REPL) released its earnings results on Wednesday. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.02, Bloomberg Earnings reports.
Shares of NASDAQ:REPL traded up $0.39 during midday trading on Thursday, reaching $10.44. The company had a trading volume of 90 shares, compared to its average volume of 24,714. The company has a debt-to-equity ratio of 0.05, a quick ratio of 14.26 and a current ratio of 14.26. The company’s 50 day moving average is $12.78. The firm has a market capitalization of $322.99 million and a PE ratio of -7.83. Replimune Group has a 1-year low of $8.88 and a 1-year high of $23.55.
A number of analysts recently issued reports on the company. JPMorgan Chase & Co. raised Replimune Group from a “neutral” rating to an “overweight” rating and lowered their target price for the company from $27.00 to $26.00 in a research report on Friday, July 12th. Zacks Investment Research raised Replimune Group from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Wednesday, July 3rd. HC Wainwright assumed coverage on Replimune Group in a research report on Monday, July 8th. They issued a “buy” rating and a $26.00 target price on the stock. Wedbush assumed coverage on Replimune Group in a research report on Wednesday, April 24th. They issued an “outperform” rating and a $24.00 target price on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $28.00 target price on shares of Replimune Group in a research report on Thursday. Six research analysts have rated the stock with a buy rating, Replimune Group presently has a consensus rating of “Buy” and an average target price of $24.00.
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Further Reading: Golden Cross
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.